Everence Capital Management’s Roivant Sciences ROIV Stock Holding History

Everence Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$560K	Buy	15,820 +2,140	+16%	+$63.2K	0.03%	388
2026 Q1	$379K	Hold	13,680	–	–	0.02%	470
2025 Q4	$297K	Hold	13,680	–	–	0.02%	591
2025 Q3	$207K	Hold	13,680	–	–	0.01%	761
2025 Q2	$154K	Hold	13,680	–	–	0.01%	771
2025 Q1	$138K	Hold	13,680	–	–	0.01%	768
2024 Q4	$162K	Buy	+13,680	New	+$162K	0.01%	804

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Everence Capital Management's ROIV Position: Q2 2026 in Review

Everence Capital Management increased its Roivant Sciences (ROIV) stake by 16% in Q2 2026, buying an estimated $63.2K and bringing the position to 15,820 shares worth $560K. The position accounts for 0.03% of the portfolio, ranked #388.

Everence Capital Management first reported a position in ROIV in Q4 2024 and has held it in 7 quarters since. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Everence Capital Management held 15,820 shares of Roivant Sciences worth $560K as of Q2 2026.
Everence Capital Management bought 2,140 Roivant Sciences shares in Q2 2026, an estimated $63.2K.
Roivant Sciences made up 0.03% of Everence Capital Management's portfolio in Q2 2026, its #388 holding.
Everence Capital Management first reported a position in Roivant Sciences in Q4 2024 and has held it in 7 quarters since.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.